开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

休市中 12-19 16:08:04

1.940

+0.030

+1.57%

最高1.980	最低1.930	成交量29.70万
今开1.930	昨收1.910	日振幅2.62%
总市值9.68亿	流通市值9.68亿	总股本4.99亿
成交额58.01万	换手率0.06%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.94,"timestamp":1766131684309,"preClose":1.91,"halted":0,"volume":297000,"delay":0,"floatShares":499000000,"shares":499000000,"eps":-0.3989897163233704,"marketStatus":"休市中","change":0.03,"latestTime":"12-19 16:08:04","open":1.93,"high":1.98,"low":1.93,"amount":580140,"amplitude":0.026178,"askPrice":1.97,"askSize":44000,"bidPrice":1.94,"bidSize":24500,"shortable":0,"etf":0,"ttmEps":-0.42743404430818077,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":7,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.91,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":0.6999764316379965,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2592546146","title":"900亿医药巨头 创二代接任首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=2592546146","media":"中国基金报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592546146?lang=zh_cn&edition=full","pubTime":"2025-12-20 22:02","pubTimestamp":1766239372,"startTime":"0","endTime":"0","summary":"【导读】石药集团董事会主席蔡东晨之子蔡磊接任公司首席执行官在旗下A股上市公司新诺威（石药创新）向港交所递交招股书后不久，石药集团宣布，董事会主席蔡东晨之子、执行董事蔡鑫之兄蔡磊，接任公司董事会副主席、CEO（首席执行官）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512203597499846.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512203597499846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1161","BK1574","159938","09939"],"gpt_icon":0},{"id":"2592711132","title":"商务部发布2026年甘草及甘草制品出口配额公开招标投标企业名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2592711132","media":"北京日报客户端","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592711132?lang=zh_cn&edition=full","pubTime":"2025-12-19 11:45","pubTimestamp":1766115900,"startTime":"0","endTime":"0","summary":"转自：北京日报客户端根据商务部2025年第78号公告，经审核，现将2026年甘草及甘草制品出口配额公开招标投标企业名单发布如下：一、符合鲜或干的甘草投标资格的企业（76家）1.亳州市中药饮片厂2.安徽贺林中药饮片科技有限公司3.安徽和济堂中药饮片有限公司4.安徽谓博中药股份有限公司5.安徽省本草国药饮片有限公司6.安徽盛林国药饮片有限公司7.亳州市盛林中药饮片有限公司8.安徽省天和中药材开发有限公","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-19/doc-inhcicep7777788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","BK1515","09939","BK1191","01477"],"gpt_icon":0},{"id":"2592345351","title":"医药股今早显著反弹 凯莱英及药明生物均涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592345351","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592345351?lang=zh_cn&edition=full","pubTime":"2025-12-19 11:05","pubTimestamp":1766113500,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　医药股今早明显反弹，CRO、创新药方向居前。截至发稿，凯莱英（06821）上涨6.07%，报76.85港元；药明生物（02269）上涨6.05%，报34.70港元；三生制药（01530）上涨4.65%，报26.58港元；诺诚健华（09969）上涨4.70%，报13.80港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-12-19/doc-inhcicep7752391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B0JY6N72.USD","159938","LU0417516738.SGD","LU0572944931.SGD","LU0327786744.USD","LU0039217434.USD","LU0051755006.USD","LU1794554557.SGD","BK1589","LU0320764599.SGD","LU0516423174.USD","LU0043850808.USD","LU0979878070.USD","BK1515","BK1574","LU0516423091.SGD","LU0348735423.USD","LU0823426480.USD","BK1161","06821","BK1141","09939","LU0181495838.USD","LU0516422366.SGD","LU0417516902.SGD","LU0708995583.HKD","BK1521","002821","LU0856984785.SGD","LU3063872942.SGD","BK0239","02269","LU0359201612.USD","LU0588546209.SGD","LU0456846285.SGD","BK1576","LU0823426308.USD","LU0359202008.SGD","SG9999002463.SGD","LU1328615791.USD","LU1242518857.USD","LU0456827905.SGD","LU0052750758.USD","BK1610","LU1688375341.USD","LU0516422952.EUR","LU1720050803.USD","SG9999002562.SGD","LU0140636845.USD","LU0819121731.USD"],"gpt_icon":0},{"id":"2592139047","title":"医药外包概念普遍走高 药明生物(02269)涨6.11% 机构看好看好CXO在业绩和估值端迎来双重修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2592139047","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592139047?lang=zh_cn&edition=full","pubTime":"2025-12-19 10:26","pubTimestamp":1766111188,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念普遍走高，药明生物 涨6.11%，凯莱英升5.52%，康龙化成升4.69%，泰格医药升3.8%，维亚生物升3.72%，药明康德涨3.32%。世纪证券此前研报指出，本周NDAA法案落地，地缘风险趋于缓和。CXO业绩和新增订单开始好转，本周市场开始关注临床前安评试验资产食蟹猴。该机构认为CXO作为创新药产业链上游，行业经历过完整周期，有望受益于国产创新药竞争力提升带来的景气度回升，看好CXO在业绩和估值端迎来双重修复。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"66afc1ba6d0078bbc724c4259409298b","theme_name":"🔥热榜No.19 · 港股创新药概念股集体拉升，晶泰控股三生制药涨超6%","theme_type":2,"isJumpTheme":false,"source_url":"1971871","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","LU0823426480.USD","BK1161","BK1610","CXO","BK1583","LU0819121731.USD","LU0181495838.USD","LU0320764599.SGD","LU0051755006.USD","LU0052750758.USD","01873","06821","LU0516423174.USD","03347","IE00B0JY6N72.USD","LU0708995583.HKD","LU0348825331.USD","LU2125910500.SGD","02269","SG9999002463.SGD","LU0516422952.EUR","02359","BK1589","BK1576","LU1794554557.SGD","LU0140636845.USD","LU0516422366.SGD","LU2045819591.USD","LU0516423091.SGD","BK1521","09939","LU2242644610.SGD","03759","LU0359201612.USD","LU1720050803.USD","LU0039217434.USD","LU0456827905.SGD","LU0516422440.USD","BK1191","BK1574","LU0979878070.USD","LU0348735423.USD","LU1046422090.SGD","LU3063872942.SGD","SG9999002562.SGD","LU1242518931.SGD","LU1880383366.USD","159938","LU0043850808.USD"],"gpt_icon":0},{"id":"2592044139","title":"医药股集体走高 药明生物(02269)涨5.93% 机构料明年板块稳中向好态势延续","url":"https://stock-news.laohu8.com/highlight/detail?id=2592044139","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592044139?lang=zh_cn&edition=full","pubTime":"2025-12-19 10:23","pubTimestamp":1766111038,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股集体走高，药明生物 涨5.93%，药明合联涨4.56%，君实生物涨4.54%，康诺亚-B涨4.19%，荣昌生物涨3.98%，科伦博泰生物-B涨4.00%，泰格医药涨4.30%，复宏汉霖涨3.72%，诺诚健华涨3.26%。交银国际发布医药行业周报，展望2026年，该机构认为板块稳中向好态势延续，但影响市场表现的核心因素或呈分化态势，后续选股逻辑或将重回基本面和估值，即关注存在基本面预期差、当前仍被低估的个股。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971870","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","02162","BK1576","SG9999014674.SGD","LU0348735423.USD","LU0516422366.SGD","SG9999002562.SGD","03347","BK1587","02696","IE00B0JY6N72.USD","02268","LU0856984785.SGD","LU1688375341.USD","LU0327786744.USD","HK0000165453.HKD","09995","LU0196878994.USD","09969","LU0181495838.USD","BK1610","LU1242518857.USD","LU0417516902.SGD","LU1242518931.SGD","LU1969619763.USD","BK1141","BK1521","09939","LU0052750758.USD","LU0348825331.USD","LU2328871848.SGD","LU0588546209.SGD","01877","BK1574","LU0051755006.USD","LU0417516738.SGD","LU0359202008.SGD","02269","LU2488822045.USD","LU0572944931.SGD","LU0823426308.USD","LU0039217434.USD","LU1880383366.USD","LU0823426480.USD","LU0819121731.USD","LU0326950275.SGD","159938","LU0359201612.USD","BK1161","LU0708995583.HKD"],"gpt_icon":0},{"id":"2592131496","title":"招商证券：医药板块创新药产业链仍是主线 重点关注小核酸等技术方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2592131496","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592131496?lang=zh_cn&edition=full","pubTime":"2025-12-19 10:17","pubTimestamp":1766110668,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券发布研报称，2026年医药板块在创新出海持续兑现、医疗内需分化的产业趋势下，有望出现结构行情。创新药产业链仍是主线，除观察二代IO、减重、ADC板块的临床数据外，尤其关注小核酸技术方向的加速发展；同时关注CXO、上游、原料药中具备景气度与业绩兑现的公司。创新及药品产业链CXO：在2025年以来，外需CXO业绩逐步兑现，分子类型持续革新带来新的产业机会；内需CRO需求结构性改善，新签订单持续增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1161","BK0183","BK1574","09939","06099","BK0012","BK1564","159992","600999","BK0010","BK0188","BK1515","BK0028","BK0276","159938","BK1147"],"gpt_icon":0},{"id":"2592138956","title":"九州通医药集团股份有限公司获准注册60亿元债务融资工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2592138956","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592138956?lang=zh_cn&edition=full","pubTime":"2025-12-19 08:09","pubTimestamp":1766102998,"startTime":"0","endTime":"0","summary":"中访网数据  九州通医药集团股份有限公司近日收到中国银行间市场交易商协会下发的《接受注册通知书》，公司超短期融资券和中期票据的注册申请获得通过。根据通知书，公司超短期融资券注册金额为30亿元，由招商银行、中国光大银行等五家机构联席主承销；中期票据注册金额同样为30亿元，由中信银行、中国光大银行等六家机构联席主承销。两项注册额度自通知书落款之日起2年内有效，公司在注册有效期内可分期发行。此次债务融资工具的注册发行事宜已经公司2024年第一次临时股东大会审议批准。公司表示将根据相关规则办理后续发行工作，并及时履行信息披露义务。此举有助于公司优化债务结构，拓宽融资渠道。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251219/31875929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159938","09939","BK0012","BK0188","BK1515","BK1574","BK1161","BK0183","BK0028","BK0077","600998","BK0187","BK0201","BK0097","BK0039","BK0146","BK0196","BK0250"],"gpt_icon":0},{"id":"2592868251","title":"国泰海通｜医药：医保收入增长平稳，支出同比放缓","url":"https://stock-news.laohu8.com/highlight/detail?id=2592868251","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592868251?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:07","pubTimestamp":1766066820,"startTime":"0","endTime":"0","summary":"报告导读：2025年1-10月，医保统筹基金收入增长平稳，支出同比放缓，其中城乡居民医保收入和支出均小幅下降。报告来源以上内容节选自国泰海通证券已发布的证券研究报告。报告名称：医保收入增长平稳，支出同比放缓；报告日期：2025.12.16 报告作者：余文心（分析师），登记编号：S0880525040111赵峻峰（分析师），登记编号：S0880519080017重要提醒本订阅号所载内容仅面向国泰海通证券研究服务签约客户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650535404&idx=5&sn=0450fea1371b7aac7a332837b1c90943&chksm=894d3bbb3059089ca3efd63a9abbcffaef7b4fc7bf5a149f9729ce3ef22987c6b0bd2d8ec352&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["601211","02611","BK0188","BK1147","09939","BK0184","BK1564","BK0201","159938","BK0276","BK1574","BK0183","BK0028","BK1161","BK1515","BK0012"],"gpt_icon":0},{"id":"2592163435","title":"每日并购资讯 | 华菱线缆控股三竹科技；阿布扎比国家石油公司完成对科思创的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2592163435","media":"易界DealGlobe","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592163435?lang=zh_cn&edition=full","pubTime":"2025-12-18 19:04","pubTimestamp":1766055899,"startTime":"0","endTime":"0","summary":"中金公司换股吸收合并东兴证券、信达证券2025 年 12 月 17 日晚间披露重大资产重组预案，三家公司股票于 12 月 18 日复牌。境外阿布扎比国家石油公司完成对科思创的收购阿布扎比XRG完成对德国科思创的自愿收购，并追加11.7亿欧元增资强化其资产负债表，创下阿拉伯国企对德企最大并购纪录，科思创将借此加速“可持续未来”战略转型。截至 9 月 27 日的九个月内，该公司营收 206 亿美元，净利润 9.77 亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218204520a6b2aab4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218204520a6b2aab4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","BK1521","BK1227","00874","09939","BK1161","BK1606","01346","BK1515","BK1197"],"gpt_icon":0},{"id":"2592974327","title":"利好来了！刚刚，重磅发布！","url":"https://stock-news.laohu8.com/highlight/detail?id=2592974327","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592974327?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:37","pubTimestamp":1766050620,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　中医药赛道迎来重磅利好政策。　　今日，香港特区政府正式发布《中医药发展蓝图》，其中涵盖5个领域、8个目标以及20个行动，推动香港中医药全方位、高质量和高水平发展。　　有券商机构指出，中医药行业短期基数压力有望缓解，渠道库存加速出清，看好年底需求回暖，及后续基本面和估值改善机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-12-18/doc-inhcfkvf6637091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SINA","09939"],"gpt_icon":0},{"id":"2592997683","title":"每日卖空追踪 | 同源康医药-B 12月18日卖空量成交2万股，卖空比例为1.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592997683","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592997683?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:30","pubTimestamp":1766046628,"startTime":"0","endTime":"0","summary":"同源康医药-B北京时间12月18日，跌0.36%，卖空量成交2万股，较上一交易日减少20%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163422a6b1b434&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163422a6b1b434&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09939","BK1515","02410"],"gpt_icon":0},{"id":"2592718602","title":"劲方医药-B12月18日主力净流出50.6万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2592718602","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592718602?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:16","pubTimestamp":1766045762,"startTime":"0","endTime":"0","summary":"12月18日, 劲方医药-B股价跌2.27%，报收26.74元，成交金额660.3万元，换手率0.07%，振幅2.56%，量比0.48。劲方医药-B今日主力资金净流出50.6万元，上一交易日主力净流出0万元。该股近5个交易日下跌4.86%，主力资金累计净流出143.6万元；近20日主力资金累计净流入419.0万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218162348a6b1a658&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218162348a6b1a658&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","BK1515","02595","BK1574"],"gpt_icon":0},{"id":"2592588924","title":"华泰 | 医药深度：CXO拐点已至，新周期启航","url":"https://stock-news.laohu8.com/highlight/detail?id=2592588924","media":"华泰睿思","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592588924?lang=zh_cn&edition=full","pubTime":"2025-12-18 07:50","pubTimestamp":1766015400,"startTime":"0","endTime":"0","summary":"CXO行业外部扰动因素已边际改善，伴随海外降息、国内复苏、叠加产业升级三重驱动，行业已开启新一轮高景气周期。我们看好CXO板块后续有望迎来业绩与估值的戴维斯双击，推荐外需型且具备新分子布局优势的龙头。药企在选择CXO供应商时亦更加谨慎（重点关注资金链、服务质量、","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5NDI5MDQwMg==&mid=2649838559&idx=2&sn=a93572ab318bad055faa1dbc754a53ed&chksm=89d48d7fdc9079ae45d28fca227aa45f5a7110cc82b97ead2a34f76b0590b271a9c4c771a009&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1161","CXO","BK1574","BK1515","09939","159938"],"gpt_icon":0},{"id":"2592891610","title":"星昊医药（920017）披露募投项目延期公告，12月17日股价上涨0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592891610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592891610?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:41","pubTimestamp":1765982476,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，星昊医药报收于18.69元，较前一交易日上涨0.16%，最新总市值为23.36亿元。该股当日开盘18.58元，最高18.84元，最低18.34元，成交额达3286.95万元，换手率为1.44%。公司董事会已审议通过延期事项，独立董事发表同意意见，保荐机构无异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700040308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","BK1515","09939","BK1161"],"gpt_icon":0},{"id":"2592915570","title":"热景生物（688068）披露对舜景医药增资及股权激励暨关联交易公告，12月17日股价下跌1.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592915570","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592915570?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:18","pubTimestamp":1765981103,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，热景生物报收于170.4元，较前一交易日下跌1.15%，最新总市值为157.97亿元。该股当日开盘172.14元，最高174.42元，最低165.58元，成交额达2.97亿元，换手率为1.9%。公司近日发布公告称，于2025年12月17日召开2025年第五次临时股东会，审议通过《关于公司对舜景医药增资、受让股权同时舜景医药实施股权激励暨关联交易的议案》。该项议案已获得通过，且中小投资者表决情况已单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700039580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","688068","BK1161","BK1574","BK0239","09939","BK1515"],"gpt_icon":0},{"id":"2592691845","title":"华昊中天医药-B(02563)：优替德隆治疗乳腺癌脑转移美国关键临床研究首例患者用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2592691845","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592691845?lang=zh_cn&edition=full","pubTime":"2025-12-17 21:29","pubTimestamp":1765978175,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华昊中天医药-B 发布公告,本公司全资美国子公司Biostar Pharma, Inc.已完成其一项重要海外临床研究的首例患者给药：UTD1联合卡培他滨治疗HER2阴性乳腺癌脑转移美国关键注册临床研究。优替德隆也被美国FDA授予治疗乳腺癌脑转移的孤儿药资格。晚期乳腺癌患者约20–50%会发生脑部转移。优替德隆有望改变现状，为这类患者带来新的治疗手段和生存希望。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","159938","BK1574","BK1161","02563","09939"],"gpt_icon":0},{"id":"2592947946","title":"深耕医疗健康市场 科赴与华润医商、亿胜医药开启战略新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2592947946","media":"中国经济新闻网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592947946?lang=zh_cn&edition=full","pubTime":"2025-12-17 19:38","pubTimestamp":1765971483,"startTime":"0","endTime":"0","summary":"中国经济新闻网讯 近日，消费者健康领导企业科赴中国宣布与华润医药商业集团有限公司、珠海亿胜医药有限公司启动战略新合作。科赴将借助华润医商、亿胜医药在医疗健康市场的覆盖网络和销售能力，深入布局医疗专业渠道，助力科赴旗下的优质产品惠及更多中国患者与消费者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217194334a6ade07f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217194334a6ade07f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0979878070.USD","LU0791591158.USD","LU1807302812.USD","LU0594300179.USD","LU1023057109.AUD","LU0251144936.SGD","LU1152091168.USD","09939","LU1242518857.USD","LU0067412154.USD","LU1366334578.USD","BK1521","LU0359202008.SGD","LU0048597586.USD","LU3063872942.SGD","LU0048580855.USD","LU2088748376.SGD","LU0516423174.USD","BK1555","LU0594300419.USD","BK1574","LU0880133367.SGD","LU0738912210.USD","LU0348825331.USD","LU2088748020.USD","LU0501845795.SGD","SG9999014674.SGD","LU0516422440.USD","01109","SG9999010078.USD","BK1515","LU1008478684.HKD","SG9999010052.SGD","LU0516423091.SGD","LU0516422952.EUR","SG9999009997.SGD","LU0287142896.SGD","LU0605514214.HKD","BK1161","LU0370786039.SGD","LU1960683339.HKD","LU0414403682.SGD","LU1993786604.SGD","BK1570","LU0516422366.SGD","IE0008368742.USD","LU0791590937.USD","LU0173614495.USD","LU2088747725.USD","LU0417516902.SGD"],"gpt_icon":0},{"id":"2592991261","title":"白云山最新公告：子公司广州医药拟5.005亿元收购浙江医工100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2592991261","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592991261?lang=zh_cn&edition=full","pubTime":"2025-12-17 19:19","pubTimestamp":1765970393,"startTime":"0","endTime":"0","summary":"白云山(600332.SH)公告称，公司下属控股子公司广州医药与浙江海正药业签署股权交易合同及补充协议，广州医药拟通过公开摘牌方式受让海正药业所持浙江省医药工业有限公司100%股权，转让价款为5.005亿元。本次收购不构成关联交易，不构成重大资产重组，但需通过中国反垄断审查机构进行经营者集中审查，交易尚存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700031414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0096","BK1606","00874","BK1515","BK0012","BK1521","BK0188","159938","BK0183","BK1161","600332","BK0028","BK0097","BK1574","BK1197","BK0175","BK0070","BK0196","09939","BK1191"],"gpt_icon":0},{"id":"2592791103","title":"57.5亿！华润系确定重磅合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2592791103","media":"赛柏蓝","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592791103?lang=zh_cn&edition=full","pubTime":"2025-12-17 18:57","pubTimestamp":1765969054,"startTime":"0","endTime":"0","summary":"本次为持续关联交易的深化合作，合作期限与规模均显著提升。期内总营收为45.25亿元，同比下降9.1%；净利润3.74亿元，同比减少26.9%。华润医药营收增速在2024年显著回落，由2023年的12.20%降至5.26%；而利润端的放缓趋势则更早显现，增速从2022年的20.44%下滑至2024年的8.5%。还有近日引发业内热议的江中药业改名为华润江中，则进一步彰显了华润系统一市场形象，消除内部品牌壁垒，实现协同的决心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217194432a456cff3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217194432a456cff3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","03320","BK1574","BK1570","09939","BK1161","01515","01109"],"gpt_icon":0},{"id":"2592995117","title":"欧康医药（920230）披露高级管理人员离任公告，12月17日股价上涨0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592995117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592995117?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:49","pubTimestamp":1765964959,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，欧康医药报收于12.68元，较前一交易日上涨0.08%，最新总市值为12.77亿元。近日，欧康医药发布公告称，公司高级管理人员曹永强先生因个人原因辞去董事会秘书、财务总监职务，自2025年12月12日起生效。曹永强持有公司股份98,100股，占总股本的0.0974%，非失信联合惩戒对象，离任后不再担任公司及控股子公司任何职务，无未履行完毕的公开承诺。公司董事会对曹永强在职期间的贡献表示感谢。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700028310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","09939","159938","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.0202},{"period":"1month","weight":-0.0628},{"period":"3month","weight":-0.2761},{"period":"6month","weight":0.3108},{"period":"1year","weight":0.9596},{"period":"ytd","weight":1}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.063412},{"month":2,"riseRate":0.8,"avgChangeRate":0.219909},{"month":3,"riseRate":0.4,"avgChangeRate":0.084454},{"month":4,"riseRate":0.6,"avgChangeRate":0.421119},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.187435}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}